Lamivudine Teva Pharma B.V. 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IAIN/0030 
C.I.z - Changes (Safety/Efficacy) of Human and 
21/04/2023 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0029 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/01/2022 
30/09/2022 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Labelling and 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
PL 
new additional data is required to be submitted by 
the MAH 
IB/0028/G 
This was an application for a group of variations. 
08/10/2021 
30/09/2022 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0027/G 
This was an application for a group of variations. 
02/07/2021 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0026 
A.7 - Administrative change - Deletion of 
02/02/2021 
23/07/2021 
Annex II and 
Page 2/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing sites 
PL 
IB/0025/G 
This was an application for a group of variations. 
08/06/2020 
23/07/2021 
SmPC, 
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
Labelling and 
PL 
IA/0024 
A.7 - Administrative change - Deletion of 
10/12/2019 
n/a 
manufacturing sites 
IB/0023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
18/11/2019 
16/12/2019 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IAIN/0022 
B.III.1.a.3 - Submission of a new/updated or 
11/02/2019 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IAIN/0021 
C.I.z - Changes (Safety/Efficacy) of Human and 
22/11/2018 
22/11/2019 
SmPC 
Veterinary Medicinal Products - Other variation 
Page 3/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0020/G 
This was an application for a group of variations. 
24/10/2018 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0019 
C.I.2.a - Change in the SPC, Labelling or PL of a 
20/04/2018 
28/09/2018 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0018 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/10/2017 
28/09/2018 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0017/G 
This was an application for a group of variations. 
29/08/2016 
16/09/2016 
SmPC, Annex 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
II, Labelling 
and PL 
Page 4/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0016 
A.7 - Administrative change - Deletion of 
29/03/2016 
16/09/2016 
Annex II and 
manufacturing sites 
PL 
II/0014/G 
This was an application for a group of variations. 
17/03/2016 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
Page 5/10 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.f - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Change outside the 
approved specifications limits range for the AS 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
B.III.2.z - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Other 
variation 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/01/2016 
18/02/2016 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
01/07/2015 
18/02/2016 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
Page 6/10 
 
 
 
 
 
 
 
 
 
the MAH 
IB/0012 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/02/2015 
18/02/2016 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
T/0011 
Transfer of Marketing Authorisation 
05/11/2014 
17/11/2014 
SmPC, 
Labelling and 
PL 
R/0009 
Renewal of the marketing authorisation. 
24/07/2014 
11/09/2014 
SmPC 
Based on the review of the available information and on the 
IAIN/0010/G 
This was an application for a group of variations. 
15/04/2014 
11/09/2014 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
basis  of a re-evaluation of the benefit risk balance, the 
CHMP is of the opinion that the quality, safety and efficacy 
of this medicinal product continues to be adequately and 
sufficiently demonstrated and therefore considered that the 
benefit risk profile of Lamivudine Teva Pharma B.V. 
continues to be favourable. The CHMP is of the opinion that 
the renewal can be granted with unlimited validity. 
Page 7/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0008/G 
This was an application for a group of variations. 
10/02/2014 
11/09/2014 
SmPC, Annex 
II, Labelling 
and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0007 
C.I.z - Changes (Safety/Efficacy) of Human and 
31/05/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IAIN/0006/G 
This was an application for a group of variations. 
13/04/2012 
28/06/2012 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
Page 8/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0005/G 
This was an application for a group of variations. 
30/03/2012 
28/06/2012 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II/0003/G 
This was an application for a group of variations. 
17/02/2011 
01/03/2011 
To register an additional manufacturing process and 
change the test procedure for the active substance 
lamivudine. 
B.I.a.2.b - Changes in the manufacturing process of 
the AS - Substantial change to the manufacturing 
process of the AS which may have a significant 
impact on the quality, safety or efficacy of the 
medicinal product 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
Page 9/10 
 
 
 
 
 
 
 
 
 
 
 
 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IA/0001 
IA_07_a_Replacement/add. of manufacturing site: 
13/01/2010 
n/a 
Secondary packaging site 
Page 10/10 
 
 
 
 
 
 
 
 
 
 
